Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Is €20m A Reasonable Cost For An EU PIP? Consultation On Pediatric Rule

Executive Summary

Biosimilars, the complicated rewards system, and the costs for companies involved in carrying out a pediatric investigation plan are among the many issues discussed in the European Commission’s newly released consultation on the Paediatric Regulation nearly 10 years after it came into force.

Advertisement

Related Content

R&D-Based Industry Describes Practical Challenges Of EU Paediatric Regulation
‘Not What We Expected,’ R&D Industry Says Of ‘Onerous’ EU Paediatric Regulation
Pharma Attacked For “Playing The System” Of EU Pediatric Rewards
EMA Wants Authority To Request Modifications To Agreed PIPs

Topics

Advertisement
UsernamePublicRestriction

Register

PS119549

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

All set! This Question has been sent to my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel